Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

Inclusion Criteria:

Histologically/cytologically confirmed adenocarcinoma of the breast, followed by adequate surgical resection and/or radiotherapy, and/or adjuvant chemotherapy, if indicated.
Stage T1-3 N0-2 Mo, Any TNM stage BC for whom adjuvant hormonal therapy is being considered.

Exclusion Criteria:

Those patients not deemed to have had potentially curative primary surgical treatment or one of the following criteria:
Inflammatory breast cancer
Histologically positive supraclavicular nodes
Ulceration/infiltration of local skin metastasis
Neoadjuvant chemotherapy
Ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) without invasion
ER and PR negative primary tumor or ER/PR unknown status.